Alkem Laboratories Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Press Release".
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Midcap 150 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alkem Laboratories' wholly-owned medical devices subsidiary, Alkem MedTech, has signed a binding offer to acquire up to 55% stake in Occlutech Holding AG, a Switzerland-headquartered company specialising in minimally invasive cardiac implants. The deal is valued at EUR 99.4 million (approximately INR 1,074 crore). Occlutech is the second-largest player in Europe and third-largest globally in this segment, with CY2025 revenue of EUR 49.4 million (unaudited) and a 15.7% three-year CAGR, deriving about 85% of revenue from Europe and the US. The acquisition gives Alkem MedTech a foothold in advanced cardiovascular devices and high-value markets such as the US, Japan, and Western Europe. The transaction is subject to definitive agreements, foreign investment clearances, and other regulatory approvals, and is expected to close by June 2026. BCG advised on the transaction.
This is a sizable international acquisition (over INR 1,000 crore) that signals Alkem's strategic push beyond pharmaceuticals into the high-margin medical devices space, potentially expanding long-term growth avenues. Near-term, the stock may react to the diversification story, though deal closure remains contingent on regulatory approvals expected by mid-2026.